CA-BOEHRINGER-INGELHEIM
9.1.2023 17:01:41 CET | Business Wire | Press release
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World Governments Summit 2027 Date Announced, Following Largest-Ever Global Participation10.2.2026 22:06:00 CET | Press release
Largest edition in the summit’s history convened 6,250+ global leaders, policymakers, and experts from 150+ countriesWorld leaders, including presidents from Switzerland, Sierra Leone, and beyond, lead strategic dialogues Under the leadership of UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the World Governments Summit concluded in Dubai with its largest-ever participation, featuring more than 6,250 attendees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210283291/en/ World Governments Summit 2026 concludes in Dubai with record participation, bringing together more than 6,250 global leaders from over 150 countries to advance dialogue on governance, innovation, and sustainable development (Photo: AETOSWire) A Global Platform Convening Global Leaders Held in Dubai from 3 to 5 February, t
Palantir and Airbus Extend Strategic Collaboration10.2.2026 22:01:00 CET | Press release
Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform. The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges. This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-ed
Grand Prix ACF AutoTech 2026 Unveils Its Six Finalist Startups10.2.2026 19:31:00 CET | Press release
The jury of the Grand Prix ACF AutoTech 2026, which met on February 9 at the Automobile Club de France, has selected six finalist startups following several hours of deliberation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210456562/en/ Jury members The selected companies stand out for their technological ambition, economic viability and tangible impact on automotive cost reduction and industrial performance. Key themes this year include AI-assisted engineering design, strategic independence from critical materials, and advanced LiDAR optimization. Finalist startups include: Grand Prix ACF (Mature startups) - Altrove (Paris, France): Develops innovative alternatives to high-risk critical inorganic materials using a proprietary algorithmic approach and unique artificial intelligence, strengthening industrial resilience and technological sovereignty. - Cognitive Design Systems (Toulouse, France): Provides an AI-powered
Second to None in Business Excellence: Mary Kay Named #2 on the Forbes 2026 Best Customer Service List10.2.2026 17:01:00 CET | Press release
Mary Kay Wraps up 2025 with 25 Corporate Reputation Awards Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. The honor follows a standout year for Mary Kay, which concluded 2025 with a total of 25 global awards, underscoring its continued focus on corporate excellence, direct selling industry, social impact, environmental sustainability, science, and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210599426/en/ Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. (Image Courtesy: Mary Kay Inc.) The recent recognition highlights Mary Kay’s enduring commitment to putting the custome
Interactive Brokers Expands Crypto Futures Offering with Coinbase Derivatives10.2.2026 16:15:00 CET | Press release
Select nano and Perpetual Style Futures Contracts Available Around the Clock Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Coinbase Derivatives, LLC nano Bitcoin and nano Ether futures contracts for trading on the IBKR platform. These new products are available with monthly expirations or as perpetual-style contracts, offering eligible clients a cost-effective way to gain exposure to cryptocurrency and manage risk within a regulated framework, with trading available 24/7. Clients of Interactive Brokers can access more than 170 markets worldwide and trade both traditional instruments and digital assets from a single platform. The new Coinbase Derivatives contracts offer an easier way to manage cryptocurrency exposure, with lower capital requirements and transparent trading on a regulated exchange. Nano futures are smaller-sized contracts, such as 0.01 Bitcoin and 0.10 Ether, that lower entry costs and allow for more precise posi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom